IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a patent from Divisional Direction of Patents, Mexico. The agency issued a Granting Office Action (“GOA”) for IGC Pharma’s treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” According to the announcement, the company believes that the success of the patent in Mexico could “pave the way” for similar approvals in the United States and Europe. The company is currently conducting a phase 2 trial investigating its lead therapeutic candidate, IGC-AD1, as a treatment for agitation in Alzheimer’s disease, one of the most common forms of a central nervous system disorder (“CNS”). IGC-AD1 is a partial CB1 receptor agonist designed with antineuroinflammatory properties to address the underlying neurodegeneration resulting in neuropsychiatric symptoms. In addition to Mexico, the company is seeking patent protection for IGC-AD1 in countries, including the United States and Canada as well as several countries in Europe. The approval from Mexico “marks an important milestone in helping set the stage for potential commercialization,” the company stated in the press release.
To view the full press release, visit https://ibn.fm/CBI8a
About IGC Pharma
IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. The company’s portfolio comprises five assets, all with a singular mission: to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is a CB1r partial agonist currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s. TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. For more information, visit the company’s website at www.IGCInc.us.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN